Press Releases
12.03.2013
MPI of Biochemistry, LDC and Qurient Close License Deal on a New Compound against Metastatic and Drug-resistant Cancers
The Max Planck Institute of Biochemistry (MPIB), the Lead Discovery Center GmbH (LDC) and Qurient Co., Ltd have entered into a license agreement providing Qurient with world-wide, exclusive rights to a new kinase inhibitor for the treatment of metastatic cancer. continue
25.01.2013
LDC forms Drug Discovery alliance with AstraZeneca
The Lead Discovery Center GmbH (LDC) and AstraZeneca have joined forces to discover new medicines for the treatment of human diseases with high unmet medical need. Through a two-year collaboration, AstraZeneca will add 250,000 high-quality compounds to LDC’s internal screening collection to pursue projects in the areas of oncology, neuroscience, respiratory and inflammation, cardiovascular, gastrointestinal and infection research. continue
21.01.2013
Alliance of Translational Research Centres Established to Accelerate Global Drug Development
Six of the world’s top translational health research centres today announced that they have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. continue
08.01.2013
MPG Spin-off DRDx Concludes First Round of Financing with Support from QIAGEN and High-Tech Gründerfonds
The Hennigsdorf firm Drug Response Dx GmbH (DRDx GmbH) successfully concluded its first round of financing with High-Tech Gründerfonds and QIAGEN. The investment will serve to develop a biomarker test kit for rheumatoid arthritis treatment guidance with so-called TNF-alpha inhibitors. The test is secured by a unique patent platform exclusively in-licensed by the Max Planck Society (MPG). continue
26.11.2012
Combination of two pharmaceuticals proves effective in the treatment of multiple sclerosis
Joint Press Release of the German Center for Neurodegenerative Diseases and the Max Planck Research Unit for Enzymology of Protein Folding continue
20.09.2012
Anti-Cancer Project Originating from LDC Reaches Next Milestone
Successful Transfer into Pre-Clinical Drug Development at Bayer Pharma AG continue
18.07.2012
TandemLaunch licenses new 3D technology
Max Planck Innovation, the technology transfer organization of the Max Planck Society together with the Patent Marketing Agency of Saarland Universities have licensed a new method for processing digital stereo image content to TandemLaunch Technologies, a Canada based company, which develops multimedia inventions into consumer technologies. The new “Backward-compatible Stereo 3D” technology makes it possible to watch movies in 3D, when wearing glasses, and 2D without glasses at the same ... continue
26.06.2012
CARE will come
Stem cell researcher Schöler welcomes the provision in new NRW coalition agreement for the development of the Center for Advanced Regenerative Engineering (CARE) continue
21.06.2012
Incubation: Gentle stimuli for pain relief
Life Science Inkubator promotes new research team --- Scientists from the Life Science Inkubator (LSI) in Bonn, which was established by the technology transfer organisation Max Planck Innovation with the aim of facilitating spin-offs in the field of the life sciences, want to explore new directions in the area of pain therapy. The aim is to suppress pain using weak electric and mechanical stimuli. The stimulation will be generated using special bandages with integrated high-tech chips. ... continue
17.04.2012
High-Tech Gründerfonds invests in KonTEM GmbH
Joint press release of High-Tech Gründerfonds, Max-Planck-Innovation GmbH, Center of advanced european studies and research (caesar) and KonTEM GmbH --- KonTEM GmbH, a spin-off company of the Max-Planck-Gesellschaft (MPG) and the Center of advanced european studies and research (caesar), has developed an innovative phase contrast system for transmission electron microscopes (TEM). The system combines enhanced image contrast with high object resolution and thus opens up new possibilities ... continue
22.03.2012
Glowing colours to highlight the minutest details
Max Planck Innovation and Abberior sign licensing agreement for the development of fluorescent dyes for use in high-resolution microscopy continue
21.03.2012
Researchers at the LSI in Bonn overcome the blood-brain barrier with “GPS pill”
New prospects for the treatment of brain diseases continue
05.12.2011
Max Planck Society is hosting "Green Talent" winners
Young scientists from all over the world who are seeking solutions for the advancing climate change and who are developing sustainable strategies for the preservation of our natural environment are invited to Max Planck Society and its technology transfer organization Max Planck Innovation today. The winners of the prestigious "Green Talents" competition of the German Federal Ministry of Education and Research (BMBF) have the opportunity to gather specific information about research ... continue
16.11.2011
Max Planck Innovation gets caesar spin-off KonTEM under way
Spin-off company develops phase contrast for electron microscopy continue
11.11.2011
License Agreement Between Leica Microsystems, the Max Planck Society and the German Cancer Research Center
Developing the Next STED Generation continue
15.09.2011
Max Planck Society partners with Sanofi to Develop Innovative Solutions for Restoring Vision
New collaboration reinforces Sanofi’s translational discovery platform for retinal diseases continue
12.05.2011
Research prize for invention that treats chronic wounds
A research team from the Max Planck Institute for Extraterrestrial Physics and the Klinikum Schwabing hospital was awarded the Fondation URGO’s 2010 research prize on 10 May 2011 for its plasma technology. The invention enables the destruction of bacteria in chronically infected wounds and promotes wound healing in this way. continue
11.05.2011
Software for the discovery of new crystal structures
A new software called QED (Quantitative Electron Diffraction), which has been licensed by Max Planck Innovation, has now been released by HREM Research Inc., a Japan based company, which is developing products and services in the field of High-Resolution Electron Microscopy. QED allows transmission electron microscopes to acquire novel kinds of data, opening up new possibilities in electron crystallography. continue
18.04.2011
Lead Discovery Center and Bayer enter into license agreement covering a novel pharmaceutical lead structure
Out-licensing of the first pharmaceutical lead structure generated at the Lead Discovery Center for further development into a cancer therapy. continue
10.02.2011
Evotec acquires MPS-spin-off Kinaxo
Evotec AG, a leading company in the discovery and development of novel small molecule drugs, acquired all shares of Kinaxo Biotechnologies GmbH, a Munich-based drug discovery alliance company supporting the development of targeted drugs. With the acquisition of the MPS-spin-off Kinaxo and before Develogen AG several excellent technologies from different Max-Plancks Institutes are now powerfully brought together and continued under the roof of the Evotec AG, which had also arisen from a ... continue
20.01.2011
Lead Discovery Center and Merck KGaA Enter Collaboration for the Discovery of Anti-Cancer Compounds – Research collaboration may realize the potential of kinase inhibitors as a means for cancer treatments in the future
The Lead Discovery Center GmbH (LDC), a small molecule drug discovery spin-off of Max Planck Innovation GmbH, announced today that it has signed a cooperation agreement with Merck KGaA for the discovery of kinase inhibitors as potential cancer treatments. continue
02.12.2010
Alnylam's Tuschl II Patent Fully Upheld in European Opposition Proceedings - Decision of European Patent Office Validates Significance of Exclusively Held Tuschl II Patent for RNAi Therapeutics -
27.10.2010
Max Planck Innovation licenses analysis-technology for metabolites
Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society awards an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical research. The new technology is part of an innovative procedure which makes it possible to measure and interpret virtually all chemical substances within a biological sample. This way processes in industrial biotechnology and food quality can be improved. continue
26.07.2010
Max Planck Innovation awards license for actin marker LifeAct
Max Planck Innovation and ibidi sign license agreement for cytoskeleton research Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, awards an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located in Martinsried near Munich. The novel peptide allows for actin, an important protein, to be made visible in living cells without disturbing the actin dependent processes. Therefore, cells as well as the development of ... continue
10.03.2010
Max Planck Innovation licenses innovative sampling system to bbi-biotech
Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, is concluding two exclusive licensing agreements for a liquid sampling system with bbi-biotech GmbH, an innovative biotechnology company. The technology, developed at the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg, provides a sterile and economical way of taking samples for bioprocess analysis. continue
12.11.2009
Max Planck Innovation awards license to Solexel for an innovative method to develop thin-film solar cells
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, Germany’s leading basic research organization, has signed a co-exclusive license agreement for its Porous-Silicon-Process (PSI process) technology with Solexel, Inc., a company focusing on the development and commercialisation of high-efficiency thin-film photovoltaic arrays and solar modules. continue
13.10.2009
Max Planck Innovation grants rights for developing new nanoscopic method to Leica Microsystems
Max Planck Innovation, the technology transfer organization of the Max Planck Society, grants Leica Microsystems, Wetzlar, an exclusive license for implementing the latest generation of optical microscopes with a resolution far below the diffraction limit (nanoscopes). This innovative optical nanoscopy, named GSDIM (ground state depletion microscopy followed by individual molecule return), achieves image resolutions in the nanometer range – even in conventional wide field microscopes. GSDIM ... continue
18.08.2009
Max Planck Innovation announces an exclusive licensing agreement with PerkinElmer for its Silicon Photomultiplier (SiPM) Technology
Max Planck Innovation, the technology transfer organization of the Max Planck Society, has entered into an exclusive licensing agreement with PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, for its ultra-fast, low cross-talk solid state silicon photomultiplier (SiPM) technology. continue
14.05.2009
Max Planck Innovation and LSP to launch DDC Ventures, a new pharmaceutical Venture Capital Fund
Max Planck Innovation GmbH, the technology transfer arm of Germany’s Max Planck Society, has today announced that LSP, a leading European venture fund manager, has been appointed to manage a new EUR 100 million venture capital fund. The fund will make investments into pharmaceutical projects primarily originating from the life science institutes of the Max Planck Society, one of the world’s most renowned research organisations. continue
30.09.2008
Max Planck Innovation's Drug Discovery and Development Center Wins BioPharma Strategy Competition
Project will receive €20 million in funding from the BMBF - Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society (MPG), announces today that its concept for a novel Drug Discovery and Development Center (DDC) will receive €20 million in funding from the German Ministry of Education and Research (BMBF) through its initiative "BioPharma - The strategy competition for medicine of the future". The DDC was selected as one of three winners that were presented ... continue
21.07.2008
Dafra Pharma R&D has been awarded an exclusive licence from the Max Planck Society to develop a drug against leishmaniasis
Max Planck Innovation, the technology transfer agency of the Max Planck Society based in Munich, Germany and Dafra Pharma R&D, a Belgian research company belonging to Dafra Pharma International, signed a license agreement today for the development and commercialisation of a new drug against leishmaniasis. continue
17.06.2008
Lead Discovery Center Starts Operations
Supporting the development of novel medicines in Germany - Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, announces today the opening of its new subsidiary, the Lead Discovery Center GmbH (LDC). It will be based in Dortmund, Germany, and intends to employ a staff of 15-20 experienced drug discovery scientists, project managers, and technical assistants by the end of 2008. continue
12.06.2008
Max Planck Innovation Receives IPTEC Award for Excellence in Technology Transfer
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, was honored for outstanding achievement in developing technology transfer and licensing in the public sector. The award was presented yesterday, June 11, during the third International Marketplace and Conference for Technology Transfer Professionals (IPTEC) in Frankfurt. continue
03.03.2008
Max Planck Innovation's Drug Discovery Center Selected for Final Round of the BioPharma Strategy Competition
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, announces today that its concept for a novel Drug Discovery Center (DDC) has reached the final round of the "BioPharma - strategy competition for medicine of the future", a support program of the German Ministry of Education and Research (BMBF). continue
12.12.2007
Max Planck Innovation and AmVac Enter Partnership for the Development of Novel Vaccines
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, has closed a license agreement with Swiss AmVac AG, a biopharmaceutical company focused on the development and commercialization of innovative vaccines. Under the terms of the agreement, AmVac obtains the exclusive right to further develop and commercialize a technology that enables the design and production of a new class of vaccines with improved safety and efficacy. In return, Max Planck Innovation receives ... continue
29.10.2007
Max Planck Innovation and FuMA-Tech sign exclusive licencing agreement for novel fuel cell technology
New membrane material solves crucial problem for methanol-based fuel cells continue
01.08.2007
Alnylam Receives Allowance from European Patent Office for Tuschl II Patent, Exclusively Licensed from Max Planck Society
Tuschl II Patent in Europe Covers Compositions, Methods, and Uses of Small Interfering RNAs in World's Second Largest Pharmaceutical Market / Tuschl II Patent also Granted in Australia continue
21.05.2007
Max Planck Innovation Concludes Licensing Agreement for Technology Providing Unlimited Resolution in Microscopy
Overcoming Abbe's law in light microscopy continue
15.02.2007
KeyNeurotek AG and Max Planck Society sign licence and cooperation agreement for drug development
06.02.2007
Max Planck Innovation Concludes Diagnostic microRNA Licensing Agreement
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, Germany's leading basic research organization, has signed a co-exclusive license agreement with Stratagene Corporation (NASDAQ:STGN), a developer, manufacturer and marketer of specialized life science research and diagnostic products. Under the terms of the agreement, Stratagene has been granted rights to patents covering more than 150 human microRNA sequences for use in diagnostic applications. continue
23.10.2006
From Garching Innovation to Max Planck Innovation
The technology transfer company of the Max Planck Society will operate under the new name Max Planck Innovation. continue
21.08.2006
Max Planck Research leads to EU approval for cancer medication
The European Union has now approved SUTENT®. The basic mechanism behind the medication was discovered in the 1990s by Max Planck scientists, led by Prof. Axel Ullrich. The resulting patents were licensed by Garching Innovation GmbH, the technology transfer organisation of the Max Planck Society. continue
News alert
Do you want to receive our newsletter and press releases?
Subscribe here
Media contact
Markus Berninger
Phone: (089) 290919-30